DorsaVi (ASX:DVL) ROCE % : -116.69% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is DorsaVi ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. DorsaVi's annualized ROCE % for the quarter that ended in Jun. 2024 was -116.69%.

DorsaVi ROCE % Historical Data

The historical data trend for DorsaVi's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DorsaVi ROCE % Chart

DorsaVi Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-169.45

-78.00

-71.21

-138.33

-118.45

DorsaVi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-96.32	-136.94	-127.87	-111.71	-116.69

DorsaVi ROCE % Calculation

DorsaVi's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-1.682	/	( ( (2.689 - 0.984)	+	(2.184 - 1.049) )	/ 2 )
	=	-1.682	/	( (1.705	+	1.135)	/ 2 )
	=	-1.682	/	1.42
	=	-118.45 %

DorsaVi's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-1.556	/	( ( (2.455 - 0.923)	+	(2.184 - 1.049) )	/ 2 )
	=	-1.556	/	( ( 1.532	+	1.135 )	/ 2 )
	=	-1.556	/	1.3335
	=	-116.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

DorsaVi (ASX:DVL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

DorsaVi ROCE % Related Terms

Thank you for viewing the detailed overview of DorsaVi's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

DorsaVi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Hardware » DorsaVi Ltd (ASX:DVL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-13 Milgate Street, Unit 3, Oakleigh South, Melbourne, VIC, AUS, 3167

Website

https://www.dorsavi.com

DorsaVi Ltd is engaged in the development and sale of motion analysis technologies. Its technologies are commercialized via license, sale, or fixed-fee consultancy. The company makes wearable sensors, software, and sophisticated algorithms that measure movement and muscle activation at around 200 frames per second. The company's products include ViSafe (Workplace), ViMove (Clinic), and others. The firm operates in two reportable segments: Clinical, and Workplace. A majority of its revenue is generated from the Clinical segment. Geographically, the company derives maximum revenue from the United States of America, and the rest from Australia, and Europe.

DorsaVi Headlines

No Headlines